[go: up one dir, main page]

CL2008000716A1 - Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente. - Google Patents

Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente.

Info

Publication number
CL2008000716A1
CL2008000716A1 CL200800716A CL2008000716A CL2008000716A1 CL 2008000716 A1 CL2008000716 A1 CL 2008000716A1 CL 200800716 A CL200800716 A CL 200800716A CL 2008000716 A CL2008000716 A CL 2008000716A CL 2008000716 A1 CL2008000716 A1 CL 2008000716A1
Authority
CL
Chile
Prior art keywords
patient
forecasting
ras
responding
absence
Prior art date
Application number
CL200800716A
Other languages
English (en)
Inventor
Salvatore Bardelli Alber Siena
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39666021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000716(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2008000716A1 publication Critical patent/CL2008000716A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200800716A 2007-03-13 2008-03-11 Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente. CL2008000716A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90697607P 2007-03-13 2007-03-13

Publications (1)

Publication Number Publication Date
CL2008000716A1 true CL2008000716A1 (es) 2008-09-22

Family

ID=39666021

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800716A CL2008000716A1 (es) 2007-03-13 2008-03-11 Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente.

Country Status (19)

Country Link
US (2) US20090075267A1 (es)
EP (2) EP2118322A2 (es)
JP (3) JP2010521154A (es)
AR (1) AR065686A1 (es)
AU (1) AU2008226808B2 (es)
CA (1) CA2680330A1 (es)
CL (1) CL2008000716A1 (es)
CY (1) CY1114159T1 (es)
DK (1) DK2412828T3 (es)
ES (1) ES2426814T3 (es)
HR (1) HRP20130764T1 (es)
MX (1) MX2009009779A (es)
PE (1) PE20090690A1 (es)
PL (1) PL2412828T3 (es)
PT (1) PT2412828E (es)
RS (1) RS52932B (es)
SI (1) SI2412828T1 (es)
TW (1) TW200904828A (es)
WO (1) WO2008112274A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
ITBO20050646A1 (it) 2005-10-26 2007-04-27 Silicon Biosystem S R L Metodo ed apparato per la caratterizzazione ed il conteggio di particelle
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
DK2412828T3 (da) * 2007-03-13 2013-09-02 Amgen Inc K-ras og B-raf-mutationer og anti-EGFr-antistofbehandling
SI2465950T1 (sl) * 2007-03-13 2017-11-30 Amgen Inc. Mutacije K-ras in terapija s protitelesi anti-EGFR
ITTO20070771A1 (it) 2007-10-29 2009-04-30 Silicon Biosystems Spa Metodo e apparato per la identificazione e manipolazione di particelle
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US10895575B2 (en) 2008-11-04 2021-01-19 Menarini Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
DK3301446T3 (da) * 2009-02-11 2020-06-29 Caris Mpi Inc Molekylær tumorprofilering
CN101487051B (zh) * 2009-02-24 2011-07-20 广州益善生物技术有限公司 Braf基因突变的检测探针、液相芯片及其检测方法
NO2408562T3 (es) 2009-03-17 2018-08-04
EP2470898A4 (en) * 2009-08-24 2013-03-13 Genentech Inc DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT IN DETECTION OF K-RAS MUTATIONS AND MEASURING RTK EXPRESSION LEVELS
WO2011031840A1 (en) * 2009-09-09 2011-03-17 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
AU2011223655A1 (en) * 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
NZ602920A (en) * 2010-04-12 2014-07-25 Response Genetics Inc Kras primers and probes
CA2804335A1 (en) 2010-06-15 2011-12-22 Alberto Bardelli Mlk4 gene, a new diagnostic and prognostic marker in cancers
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
WO2012049279A1 (en) 2010-10-14 2012-04-19 Universitaet Des Saarlandes MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
ITTO20110990A1 (it) 2011-10-28 2013-04-29 Silicon Biosystems Spa Metodo ed apparato per l'analisi ottica di particelle a basse temperature
US9023640B2 (en) * 2011-12-13 2015-05-05 Fundamental Solutions Corporation Device for rapid detection of infectious agents
PT2884979T (pt) 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
WO2014052613A2 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
SG11201507739TA (en) * 2013-03-19 2015-10-29 Toppan Printing Co Ltd Method for predicting sensitivity to egfr inhibitor
CN104762371B (zh) 2014-01-07 2021-03-09 三星电子株式会社 用于预测或监控c-Met抑制剂效力的生物标志物
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
KR20160037666A (ko) 2014-09-29 2016-04-06 삼성전자주식회사 KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측
KR20180069903A (ko) 2015-11-02 2018-06-25 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도
EP4411037A3 (en) 2015-12-22 2024-11-06 Access Vascular, Inc. High strength biomedical materials
CA3067850A1 (en) 2017-06-21 2018-12-27 Access Vascular, Inc High strength porous materials incorporating water soluble polymers
CN107918013A (zh) * 2017-09-25 2018-04-17 浙江天科高新技术发展有限公司 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒
CN108085390A (zh) * 2017-12-29 2018-05-29 上海桐树生物科技有限公司 肿瘤驱动基因变异的检测剂、检测试剂盒及其应用
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
CA3124423A1 (en) 2018-12-19 2020-06-25 Access Vascular, Inc. High strength porous materials for controlled release
EP4171704A4 (en) 2020-06-30 2024-10-23 Access Vascular, Inc. ARTICLES COMPRISING MARKINGS AND ASSOCIATED PROCESSES

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
EP0636186B1 (en) 1992-04-03 1998-11-25 The Perkin-Elmer Corporation Probe composition and method
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1161563A2 (en) 1999-03-15 2001-12-12 PE Corporation (NY) Probe/mobility modifier complexes for multiplex nucleic acid detection
CA2410950A1 (en) 2000-05-30 2001-12-06 Hans-Michael Wenz Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
KR101289774B1 (ko) * 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법
US7932026B2 (en) 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
CA2601936C (en) * 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
KR20080014745A (ko) * 2005-04-01 2008-02-14 암젠 인코포레이티드 상피세포 성장인자 수용체 유전자 복제 수
JP2008535508A (ja) * 2005-04-14 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法
SI1913157T2 (sl) * 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
KR101053738B1 (ko) * 2006-08-10 2011-08-02 가부시키가이샤 우부카타 세이사쿠쇼 열응동 개폐기
DK2412828T3 (da) * 2007-03-13 2013-09-02 Amgen Inc K-ras og B-raf-mutationer og anti-EGFr-antistofbehandling
SI2465950T1 (sl) * 2007-03-13 2017-11-30 Amgen Inc. Mutacije K-ras in terapija s protitelesi anti-EGFR

Also Published As

Publication number Publication date
US20090075267A1 (en) 2009-03-19
MX2009009779A (es) 2009-09-23
AR065686A1 (es) 2009-06-24
PE20090690A1 (es) 2009-06-22
JP2010521154A (ja) 2010-06-24
EP2412828A1 (en) 2012-02-01
HRP20130764T1 (hr) 2013-10-25
TW200904828A (en) 2009-02-01
CA2680330A1 (en) 2008-09-18
ES2426814T3 (es) 2013-10-25
HK1167005A1 (en) 2012-11-16
US20110212456A1 (en) 2011-09-01
JP2015119726A (ja) 2015-07-02
EP2412828B1 (en) 2013-06-05
JP2013253105A (ja) 2013-12-19
AU2008226808B2 (en) 2013-04-18
DK2412828T3 (da) 2013-09-02
PT2412828E (pt) 2013-08-02
EP2118322A2 (en) 2009-11-18
RS52932B (sr) 2014-02-28
WO2008112274A2 (en) 2008-09-18
CY1114159T1 (el) 2016-08-31
PL2412828T3 (pl) 2013-11-29
JP5905422B2 (ja) 2016-04-20
AU2008226808A1 (en) 2008-09-18
SI2412828T1 (sl) 2013-10-30
WO2008112274A3 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CL2008000716A1 (es) Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente.
CL2008000717A1 (es) Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente.
AU323834S (en) Footwear upper
AU323837S (en) Footwear upper
AU323832S (en) Footwear upper
AU326351S (en) Footwear upper
AU323779S (en) Footwear upper
AU326409S (en) Footwear upper
AU323781S (en) Footwear upper
AU323833S (en) Footwear upper
AU326382S (en) Footwear upper
AU326386S (en) Footwear upper
TW200942466A (en) Devices and methods for performing inspections, repairs, and/or other operations within vessels
ES2570359T3 (es) Regiones ultraconservadas que codifican ARNnc
AU330150S (en) Footwear upper portion
AU331723S (en) Bottle
AU323836S (en) Footwear upper
AU326411S (en) Footwear upper
AU326324S (en) Footwear upper
AU326350S (en) Footwear upper
AU326385S (en) Footwear upper
AU326383S (en) Footwear upper
AU326352S (en) Footwear upper
AU326323S (en) Footwear upper
AU323831S (en) Footwear upper